Web- RAXONE (CAP) - PSUSA/00010412/202409 Applicant: Santhera Pharmaceuticals (Deutschland) GmbH PRAC Rapporteur: Amelia Cupelli . Scope: Evaluation of a PSUSA procedure . Action: For adoption of recommendation to CHMP . 13. Centrally authorised product(s) only . 14. Centrally authorised product(s) only WebFeb 8, 2024 · Pratteln, Switzerland, February 8, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that it has secured a final reimbursement agreement with the French …

Raxone,150 mg,film tableta

WebIntroduction: Leber's Hereditary Optic Neuropathy (LHON) causes a rapid and severe decrease in visual acuity. Raxone ® (Idebenone, Santhera) is the only drug to have a European Marketing Authorization for the treatment of this optic neuropathy. It can be proposed in the first months after the onset of this optic neuropathy, according to an … WebChiesi Farmaceutici, an international research focused healthcare group (Chiesi Group) has entered into an exclusive license agreement with Santhera Pharmaceutical, under which Chiesi Group will in-license an orphan drug whose active principle is idebenone for the treatment of Leber hereditary optic neuropathy (LHON), an ultrarare hereditary disease … north american 1008a-6

Santhera

WebJun 21, 2024 · 26 October 2024. Removal of scientific opinion for Raxone due to discontinuation of EAMS programme at the request of the company. 22 June 2024. The Annex to Public Assessment Report THIRD RENEWAL ... WebHB6PN45W4J - IDEBENONE. Η ιδεβενόνη (idebenone) είναι αντιοξειδωτικός παράγοντας που θεωρείται ικανός να μεταφέρει ηλεκτρόνια απευθείας στο σύμπλοκο ΙΙΙ, αποκαθιστώντας την παραγωγή ενέργειας από τα ... WebMay 22, 2014 · A total of 93.8% of Catena ® /Raxone ® -treated and 94.1% of placebo-treated patients experienced at least one Adverse Event (AE). Serious AEs were reported in 6.3% of Catena ® /Raxone ... north american 1199